Pfizer Inc (PFE): Total Assets
$208.16B
As of 2025-12-31
$201.13B
As of 2026-06-28
+1.8%
3-year compound annual growth
+6.2%
5-year compound annual growth
+2.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $208.16B | -2.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $213.40B | -5.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $226.50B | +14.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $197.21B | +8.7% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $181.48B | +17.7% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $154.23B | -8.0% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $167.59B | +5.1% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $159.42B | -7.2% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $171.80B | +0.1% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $171.62B | +2.5% | 2018-02-22, Balance as of period end |
| 2015-12-31 | $167.38B | -0.1% | 2017-02-23, Balance as of period end |
| 2014-12-31 | $167.57B | n/c | 2016-02-29, Balance as of period end |
| 2013-12-31 | $172.10B | -7.4% | 2015-02-27, Balance as of period end |
| 2012-12-31 | $185.80B | -1.2% | 2014-02-28, Balance as of period end |
| 2011-12-31 | $188.00B | -3.6% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $195.01B | -8.4% | 2012-02-28, Balance as of period end |
| 2009-12-31 | $212.95B | +91.6% | 2011-02-28, Balance as of period end |
| 2008-12-31 | $111.15B | n/a | 2010-02-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $133.96B | -0.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $40.75B | +3.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $40.56B | +7.4% |
Compare PFE, ABBV, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗